Multiple System Atrophy is typically considered a sporadic disorder, with over 95% of cases presenting without clear familial aggregation. However, genetic factors play an important role in disease susceptibility, pathogenesis, and phenotypic expression. This page reviews current understanding of genetic contributions to MSA, including known genetic variants, familial aggregation patterns, emerging genetic risk factors, and the interaction between genetics and environmental triggers.
MSA is closely related to Parkinson's disease, Dementia with Lewy Bodies, and other synucleinopathies. The central role of alpha-synuclein in glial cytoplasmic inclusions distinguishes MSA from other neurodegenerative diseases.
The overwhelming majority of MSA cases are sporadic, with no clear Mendelian inheritance pattern observed in most families. The typical age of onset ranges from 50-60 years, with a slight male predominance of approximately 1.3:1. Despite this predominantly sporadic presentation, genetic factors influence disease risk in several important ways:
Genetic risk factors for MSA overlap with those for Parkinson's disease, including variants in SNCA, LRRK2, and GBA. The neuroinflammation, mitochondrial dysfunction, and autophagy pathways are all implicated in MSA pathogenesis.
The α-synuclein gene (SNCA) represents the most studied and significant genetic factor in MSA, reflecting its central role in the disease's characteristic glial cytoplasmic inclusions (GCIs) [1]. Unlike Parkinson's disease where SNCA mutations and duplications cause typical Lewy body pathology, the relationship between SNCA genetics and MSA is more complex.
Key Variants and Associations:
Rep1 Polymorphism: This polymorphic dinucleotide repeat in the SNCA promoter region has been extensively studied in MSA cohorts. Longer alleles are associated with increased transcriptional activity and elevated α-synuclein expression. Meta-analyses have demonstrated an association between specific Rep1 alleles and increased MSA risk, though the effect size is modest [2].
Point Mutations: The A53T mutation, originally described in familial Parkinson's disease, has been reported in rare cases presenting with MSA phenotype. This suggests phenotypic overlap between α-synucleinopathies and supports the concept of a disease spectrum where the same mutation can lead to different pathological outcomes depending on other genetic and environmental factors.
Copy Number Variants: SNCA gene duplications and triplications, more commonly associated with PD and Dementia with Lewy Bodies, have been reported in rare MSA cases. These variants lead to increased α-synuclein expression and may modify disease risk or phenotype.
SNCA H1 Haplotype: The H1 haplotype at the SNCA locus has been implicated in MSA risk in some cohorts, though results have been inconsistent across populations [3].
Beyond DNA sequence variants, epigenetic modifications significantly influence SNCA expression in MSA:
DNA Methylation:
Histone Modifications:
Non-Coding RNA Regulation:
The glucocerebrosidase (GBA) gene has emerged as a significant genetic risk factor for MSA [@hellentholer2019]. Originally identified as a major risk factor for Parkinson's disease, GBA variants also influence susceptibility to other synucleinopathies.
Mechanisms of Risk:
The lysosomal dysfunction caused by GBA mutations leads to:
Impaired autophagy and protein clearance
Accumulation of alpha-synuclein aggregates
Neuroinflammation due to lysosomal stress
α-Synuclein Clearance: GBA mutations lead to reduced glucocerebrosidase activity, impairing lysosomal function and α-synuclein degradation [4].
Protein Misfolding: Altered GBA may affect the processing of α-synuclein, promoting the formation of toxic aggregates.
Interaction with Autophagy: GBA deficiency impairs autophagic flux, leading to accumulation of damaged proteins and organelles.
Notable Variants:
Leucine-rich repeat kinase 2 (LRRK2) variants are more strongly linked to Parkinson's disease but have been investigated in MSA with mixed results [5]. While LRRK2 mutations are not considered major risk factors for MSA, certain variants may modify disease risk or phenotype. LRRK2 is a large kinase (2527 aa) that plays roles in autophagy, lysosomal function, and cytoskeletal dynamics.
Current Understanding:
The microtubule-associated protein tau (MAPT) gene, central to Alzheimer's disease and Progressive Supranuclear Palsy, has been investigated in MSA due to tau pathology in some cases [6].
H1 Haplotype:
COQ2 variants have been reported in association with MSA in Japanese cohorts [7], though these findings have not been consistently replicated in other populations.
Findings:
While familial MSA is extremely rare, several lines of evidence support a genetic component:
Familial Aggregation: Some families show multiple affected members, though usually appearing sporadic within each generation.
Early-Onset Cases: Patients with early-onset MSA (before age 40) may have stronger genetic contribution.
Consanguinity: Reports of MSA in offspring of consanguineous parents suggest recessive inheritance in rare cases.
The search for MSA genes intersects with research on P型多系统萎缩, Lewy Body Dementia, and other neurodegenerative diseases that share overlapping genetic risk factors.
Genome-wide association studies (GWAS) in MSA have been challenging due to the disease's rarity and typically sporadic nature [blauwendraat2020]:
Altered DNA methylation patterns have been reported in MSA brain tissue [8]:
Understanding epigenetic changes in MSA offers potential therapeutic opportunities:
While no clear environmental risk factors have been established for MSA, several lines of evidence suggest potential gene-environment interactions:
Given the role of mitochondrial dysfunction in MSA, variants in mitochondrial DNA and nuclear-encoded mitochondrial genes may interact with environmental toxins:
Genetic testing for MSA is not routinely recommended for sporadic cases but may be considered in specific scenarios:
Genetic information is valuable for research purposes:
Based on available evidence, MSA genetic risk appears to be polygenic, with multiple variants of small effect contributing to overall susceptibility. The strongest evidence supports:
Genome-wide association studies have identified several novel risk loci in MSA[guo2024]:
| Locus | Gene | Function | Effect |
|---|---|---|---|
| 4p15.2 | USP25 | Ubiquitin-specific peptidase | Increased risk |
| 19q13.11 | TMEM163 | Transmembrane protein | Modest effect |
| 2q35 | ATG16L1 | Autophagy related | Alters progression |
Whole-exome sequencing has identified rare variants in MSA cases:
Genetic architecture varies by ancestry[li2023]:
European Descent:
East Asian:
DNA methylation patterns may interact with genetic risk[wang2024]:
Genetic risk factors show population-specific patterns[li2023]:
European populations:
East Asian populations:
African populations:
Geographic clustering suggests founder mutations:
MSA risk involves multiple genetic loci:
Exome sequencing reveals rare variants:
| Gene | Variant Type | Effect |
|---|---|---|
| SNCA | Missense | Variable penetrance |
| GBA | Loss-of-function | Increased risk |
| COQ2 | Missense | Founder effect |
| MAPT | Haplotype | Modified risk |
The immune-related genetic component:
Genetic variants in inflammatory genes:
Genetic variants correlate with neuroimaging:
Fluid and imaging biomarkers influenced by genetics:
Current testing considerations:
Precision medicine approaches:
Genetic information may guide treatment selection[sidhu2024]:
| Variant | Treatment Implication |
|---|---|
| GBA carriers | May respond to glucocerebrosidase modulators |
| LRRK2 variants | Consider LRRK2 inhibitors |
| APOE status | May affect response to immunotherapies |
Genetic stratification can improve trial outcomes:
Blood and CSF transcriptomics reveal:
While MSA is predominantly a sporadic disorder, genetic factors contribute significantly to disease risk and phenotype. SNCA remains the most studied gene, with emerging evidence for GBA and other loci. Understanding genetic contributions may improve diagnostic accuracy, enable personalized therapeutic approaches, and provide insights into disease mechanisms. However, the polygenic nature of MSA risk and the limited effect sizes of individual variants present challenges for clinical implementation of genetic testing.
Genetic evidence strongly implicates lysosomal dysfunction in MSA pathogenesis[kim2023]:
GBA-Mediated Effects:
Other Lysosomal Genes:
The autophagy-lysosome pathway is crucial for clearing α-synuclein aggregates[valente2020]:
| Gene | Function | MSA Relevance |
|---|---|---|
| ATG16L1 | Autophagosome formation | GWAS hit |
| LAMP2 | Lysosomal membrane | CMA dysfunction |
| TFEB | Autophagy regulation | mTOR dysregulation |
| UVRAG | Autophagosome maturation | Endosomal trafficking |
Given the role of mitochondrial dysfunction in MSA, genetic variants affecting mitochondrial function are relevant[rossi2018]:
Nuclear-Encoded Mitochondrial Genes:
Mitochondrial DNA:
Lipid dysregulation is a key feature of MSA pathogenesis[nakamura2020]:
Genetic Associations:
Therapeutic Implications:
Genetic factors may influence clinical phenotype:
| Feature | MSA-P Association | MSA-C Association |
|---|---|---|
| SNCA variants | Stronger | Variable |
| MAPT H1 | Mixed | Some association |
| GBA carriers | More common | Less common |
Genetic modifiers affect disease timing:
Genetic factors influence progression rate:
Genetic information enables personalized approaches:
The classification of GBA variants is critical for understanding their impact on MSA risk and disease phenotype[fujishiro2018]:
Severe Mutations (null alleles):
Mild Mutations (hypomorphic alleles):
Risk Modifiers:
SNCA gene duplications and triplications provide unique insights into α-synuclein dosage effects in MSA[book2018]:
Duplication Carriers:
Triplication Carriers:
Mechanistic Implications:
COQ2 variants highlight the importance of mitochondrial dysfunction in MSA pathogenesis[sato2018]:
Coenzyme Q10 Biosynthesis:
Clinical Implications:
APOE genotype influences risk across multiple neurodegenerative diseases, with emerging evidence in MSA:
APOE ε4 Allele:
APOE ε2 Allele:
Scholz SW, et al. Genetics of Multiple System Atrophy and Progressive Supranuclear Palsy: A Systemized Review. Nat Rev Neurol. 2023. ↩︎
Chen Y, et al. SNCA Rep1 polymorphism and MSA. J Neurol. 2022. ↩︎
Federoff M, et al. SNCA variants in multiple system atrophy. Mov Disord. 2019. ↩︎
Singleton AB, et al. The role of glucocerebrosidase in synucleinopathies. J Neurochem. 2017. ↩︎
Sunwoo MK, et al. LRRK2 variants in multiple system atrophy. J Parkinsons Dis. 2019. ↩︎
Babel J, et al. MAPT H1 haplotype and MSA risk. Neurobiol Aging. 2023. ↩︎
Ogawa K, et al. COQ2 mutations in multiple system atrophy. Neurology. 2018. ↩︎
Wang L, et al. Epigenetic changes in multiple system atrophy. Acta Neuropathol Commun. 2023. ↩︎